16 June 2020 - Xtandi is the first and only androgen receptor-axis-targeted therapy approved by Health Canada in three clinical disease states of prostate cancer across four indications.

Astellas announced that Health Canada, following a priority review, has approved Xtandi (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Regardless of an mCSPC patient's risk or disease volume, they may benefit from enzalutamide.

Read Astellas press release